| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -358,000 | -330,600 |
| Depreciation and amortization | 41,100 | 28,500 |
| Non-cash lease expense | 6,600 | 5,600 |
| Stock-based compensation expense | 32,400 | 20,200 |
| Deferred income taxes | 0 | 0 |
| Unrecognized tax benefits | -31,500 | -31,500 |
| Impairment of goodwill and long-lived assets | 316,700 | 316,700 |
| Gain on termination of lease | 0 | 0 |
| Gain on acquisition | 0 | 0 |
| Other non-cash adjustments | 1,600 | 300 |
| Prepaid expenses and other current assets | 3,100 | -300 |
| Trade accounts receivable | -3,600 | 15,400 |
| Inventory | 4,100 | 1,200 |
| Prepaid taxes | -2,600 | -2,100 |
| Other assets | -1,300 | -700 |
| Accounts payable | 2,800 | 3,600 |
| Accrued liabilities | -20,800 | -29,200 |
| Net cash used in operating activities | -8,800 | -29,900 |
| Capital expenditures | 10,900 | 8,100 |
| Capitalization of intangible assets | 10,500 | 7,100 |
| Proceeds from the sale of businesses, net of cash sold | 0 | - |
| Proceeds from maturities and sales of marketable investment securities | 0 | 0 |
| Net cash used in investing activities | -21,400 | -15,200 |
| Proceeds from common stock issued under stock-based compensation plans | 2,700 | 2,700 |
| Payment of tax withheld for common stock issued under stock-based compensation plans | 6,100 | 5,800 |
| Proceeds from revolving credit facility | 40,000 | 40,000 |
| Repayment of revolving credit facility | 80,500 | 20,500 |
| Proceeds from the issuance of secured long-term credit facility | 125,000 | - |
| Fees associated with the issuance of secured long-term credit facility | 8,400 | - |
| Payment on finance leases | 300 | 200 |
| Net cash provided by (used in) financing activities | 72,400 | 16,200 |
| Effect of foreign exchange rates on cash, cash equivalents, and restricted cash | 700 | 700 |
| Change in cash and cash equivalents classified as held for sale | - | 0 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 42,900 | -28,200 |
| Cash and cash equivalents at beginning of period | 111,900 | - |
| Cash and cash equivalents at end of period | 154,800 | - |
MYRIAD GENETICS INC (MYGN)
MYRIAD GENETICS INC (MYGN)